Abstract 356P
Background
Terminal cancer pain continues to be a significant morbidity. Most of the patients need intervention by pain specialists - and few still remain “difficult to treat”. In India, most of these patients do shift to alternative medicine in desperation, with active ingredients, such as steroids/cannabinoids, and few unclassified anti-tumor substances. After listing and analyzing these the two most frequently observed ones are steroids and cannabinoids wherever patients have satisfactory pain control.
Methods
An interview based study was conducted as a part of QOL Data collection, which included other symptoms (such as fatigue, cachexia, well-being etc.) in the period of 2016-2018. One of key inclusions was - patients with advanced cancer progressed on multiple lines for which there was no standard of care. After data collection, a subset analysis was conducted with reference to pain control and use of alternative medication. For ease of analysis subjects were grouped into 4 categories based on pain control with opioids and concurrent use of cannabinoids. Subjects whose nature of the medication was not known were excluded. All four groups were analyzed for the pain control with help of visual analogy scale (VAS).
Results
The baseline demographic characters in all four groups were well balanced and depicted in Table -1. Overall there were no statistically significant differences in the duration of symptoms, average dose of opioid analgesia, performance status and the stage of disease. Pain relief was better in the cannabis group, when it was used independently or in combination with opioids. No significant additional side effects pertaining to cannabis were reported by the patients. The overall qualities of life, as well as weight gain and nausea control were better in the cannabis group.
Conclusions
We could infer that Bhang [cannabis crude form], is an effective analgesic independently having synergy with opioids. It also improved overall QOL, especially in cachexia, without adverse effects. If scientifically proven with pharmaceutical grade, it will be a significant addition to the symptomatic care of terminally ill cancer patients. Though available in US, India still does not have regulatory approval for medical cannabis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract